These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 35175692)

  • 1. The Yin-Yang roles of protease-activated receptors in inflammatory signalling and diseases.
    Zhuo X; Wu Y; Fu X; Liang X; Xiang Y; Li J; Mao C; Jiang Y
    FEBS J; 2022 Jul; 289(14):4000-4020. PubMed ID: 35175692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteinases, proteinase-activated receptors (PARs) and the pathophysiology of cancer and diseases of the cardiovascular, musculoskeletal, nervous and gastrointestinal systems.
    Hansen KK; Oikonomopoulou K; Li Y; Hollenberg MD
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Jun; 377(4-6):377-92. PubMed ID: 17952408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protease-activated receptors as drug targets in inflammation and pain.
    Vergnolle N
    Pharmacol Ther; 2009 Sep; 123(3):292-309. PubMed ID: 19481569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protease-activated receptors: regulation of neuronal function.
    Saito T; Bunnett NW
    Neuromolecular Med; 2005; 7(1-2):79-99. PubMed ID: 16052040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteinase-activated receptors (PARs) as targets for antiplatelet therapy.
    Cunningham M; McIntosh K; Bushell T; Sloan G; Plevin R
    Biochem Soc Trans; 2016 Apr; 44(2):606-12. PubMed ID: 27068977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protease-activated receptors (PARs): mechanisms of action and potential therapeutic modulators in PAR-driven inflammatory diseases.
    Heuberger DM; Schuepbach RA
    Thromb J; 2019; 17():4. PubMed ID: 30976204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advocacy of targeting protease-activated receptors in severe coronavirus disease 2019.
    Subramaniam S; Ruf W; Bosmann M
    Br J Pharmacol; 2022 May; 179(10):2086-2099. PubMed ID: 34235728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biased signalling and proteinase-activated receptors (PARs): targeting inflammatory disease.
    Hollenberg MD; Mihara K; Polley D; Suen JY; Han A; Fairlie DP; Ramachandran R
    Br J Pharmacol; 2014 Mar; 171(5):1180-94. PubMed ID: 24354792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New insight into the agonism of protease-activated receptors as an immunotherapeutic strategy.
    Jiang Y; Lu L
    J Biol Chem; 2024 Feb; 300(2):105614. PubMed ID: 38159863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more.
    Ramachandran R; Hollenberg MD
    Br J Pharmacol; 2008 Mar; 153 Suppl 1(Suppl 1):S263-82. PubMed ID: 18059329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of endothelial prostacyclin synthesis by protease-activated receptors: mechanisms and significance.
    Wheeler-Jones CP
    Pharmacol Rep; 2008; 60(1):109-18. PubMed ID: 18276992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombin and protease-activated receptors (PARs) in atherothrombosis.
    Martorell L; Martínez-González J; Rodríguez C; Gentile M; Calvayrac O; Badimon L
    Thromb Haemost; 2008 Feb; 99(2):305-15. PubMed ID: 18278179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PARs in the inflammation-cancer transformation of CRC.
    Lv J; Liu J; Chao G; Zhang S
    Clin Transl Oncol; 2023 May; 25(5):1242-1251. PubMed ID: 36547764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiology and pathophysiology of proteinase-activated receptors (PARs): PARs in the respiratory system: cellular signaling and physiological/pathological roles.
    Kawabata A; Kawao N
    J Pharmacol Sci; 2005 Jan; 97(1):20-4. PubMed ID: 15655298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kallikreins and proteinase-mediated signaling: proteinase-activated receptors (PARs) and the pathophysiology of inflammatory diseases and cancer.
    Hollenberg MD; Oikonomopoulou K; Hansen KK; Saifeddine M; Ramachandran R; Diamandis EP
    Biol Chem; 2008 Jun; 389(6):643-51. PubMed ID: 18627296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteinase activated receptor (PAR) involvement in mediating arthritis pain and inflammation.
    Russell FA; McDougall JJ
    Inflamm Res; 2009 Mar; 58(3):119-26. PubMed ID: 19184346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protease-activated receptor signalling, endocytic sorting and dysregulation in cancer.
    Arora P; Ricks TK; Trejo J
    J Cell Sci; 2007 Mar; 120(Pt 6):921-8. PubMed ID: 17344429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protease-activated receptors and their biological role - focused on skin inflammation.
    Guenther F; Melzig MF
    J Pharm Pharmacol; 2015 Dec; 67(12):1623-33. PubMed ID: 26709036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges and Opportunities in Protease-Activated Receptor Drug Development.
    Hamilton JR; Trejo J
    Annu Rev Pharmacol Toxicol; 2017 Jan; 57():349-373. PubMed ID: 27618736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of visceral pain and inflammation by protease-activated receptors.
    Vergnolle N
    Br J Pharmacol; 2004 Apr; 141(8):1264-74. PubMed ID: 15051630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.